Elanco Animal Health has received U.S. Food and Drug Administration Emergency Use Authorization for its CLiK Extra wound spray, a product designed to prevent New World screwworm infestations in livestock and wildlife. The stock has pulled back 16.12% over the past seven days and 10.88% over 30 days, though its one-year total shareholder return stands at 32.69%. The most followed analyst narrative pegs fair value at $29.79 per share, implying a 25.7% upside from the latest close of $22.12, supported by expectations of six potential blockbuster product launches and innovation revenue growth in 2025. Risks include persistent foreign exchange headwinds and slower-than-expected adoption of new products such as Zenrelia.
Elanco Animal HealthFDA EUA for CLiK Extra wound spray to prevent screwworm infestations
